Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

Search results for: pain

Let’s Get Personal

David S. Pisetsky, MD, PhD | May 1, 2009

Finding cost-effective solutions in the quest for personalized medicine

Hard Work Behind the Scenes

Alfred E. Denio, MD | May 1, 2009

My first ACR board meeting gives an insider’s view

Drug Updates

Michele B. Kaufman, PharmD, BCGP | May 1, 2009

Information on safety, labeling changes, and pharmaceutical research

The Heart-SCC Puzzle

Olga Kaloudi, MD, and Marco Matucci Cerinic, MD, PhD | May 1, 2009

Identifying and treating cardiac involvement in systemic sclerosis can be a challenge

Reading Rheum

Eric Schned, MD; Michael M. Ward, MD | April 1, 2009

Handpicked Reviews of Contemporary Literature

Lyme Disease

Staff | April 1, 2009

Patient Fact Sheet

Coding Corner Question

Staff | April 1, 2009

April’s Coding Challenge

If Joe the Plumber Gets Arthritis

David S. Pisetsky, MD, PhD | April 1, 2009

Campaign figure’s connection to personalized medicine

Drug Risk Versus Benefit

Gretchen Henkel | April 1, 2009

Perceptions from the FDA, physicians, and patients

Demonstrators Demand More Money for Arthritis Research—What Could Happen?

Leslie Crofford, MD | March 1, 2009

I recently came across a fictional publication called the Not Yet Gazette with a front-page story dated November 10, 2025, entitled, “Demonstrators demand more money for arthritis research.” The fictional report gave details of a crowd of 100,000, “many in wheelchairs,” confronting the health secretary of that time. The genesis of this fictional article was the observed trend towards the aging of the population and slow growth in research funding. The article stated that, “ ‘Fiscal constraints caused by slow economic growth and resistance to tax increases have greatly reduced allocations for medical research grants in recent years,’ [the health secretary] told the delegates. ‘Unfortunately, in our current political climate, funding for health research is limited,’ she said to reporters after the meeting. ‘We have to devote our limited resources to diseases that are more immediately life-threatening.’ ”